1111P Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global Expanded Access Program (EAP)

Abstract

Mobocertinib is a first-in-class, potent, oral, irreversible tyrosine kinase inhibitor that selectively targets in-frame EGFRex20ins mutations in NSCLC. It was recently approved in the US (Sep-2021) and the UK (Mar-2022) for patients with locally advanced or metastatic NSCLC (aNSCLC) with EGFRex20ins mutations whose disease has progressed on platinum-based chemotherapy. This report describes the real-world treatment duration of mobocertinib in post-platinum EGFRexon20ins aNSCLC patients enrolled in a global EAP that provides access to mobocertinib for patients with unmet medical need.